Dr. Repke is Professor, Department of Obstetrics and Gynecology, Penn State University College of Medicine, Hershey, Pennsylvania.
The author reports no financial relationships relevant to this video.
WHAT DOES THIS MEAN FOR PRACTICE?
Oral bisphosphonates remain in our armamentarium for reducing fracture in postmenopausal patients
Ideal duration of therapy remains unclear
Counsel patients: up to 2 y of therapy reduces fracture risk; >10 y of therapy may increase fracture risk
Citation: Drieling RL, LaCroix AZ, Beresford SA, et al. Long-term oral bisphosphonate therapy and fractures in older women: the Women’s Health Initiative. J Am Geriatr Soc. 2017;65(9):1924-1931.